<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MITIGARE- colchicineÂ capsuleÂ </strong><br>Hikma Americas, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">Rx only</span><br><span class="Bold">These highlights do not include all the information needed to use colchicine safely and effectively.  See full prescribing information for MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">.</span><br><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">  (colchicine) capsules </span><span class="Bold"><br>Initial U.S. Approval: 1961</span><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<ul class="Disc"><li>MITIGARE<span class="Sup">Â®</span> is indicated for prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in adults (<a href="#_1__INDICATIONS_AND">1</a>).</li></ul>
<p class="Highlighta">Limitations of use:<br>The safety and effectiveness of MITIGARE<span class="Sup">Â®</span> for acute treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> during prophylaxis has not been studied. </p>
<p class="Highlighta">MITIGARE<span class="Sup">Â®</span> is not an analgesic medication and should not be used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from other causes.  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc"><li>0.6 mg (one capsule) once or twice daily (<a href="#_2__DOSAGE_AND">2</a>).  Maximum dose 1.2 mg/day.</li></ul>
<p class="Highlighta">MITIGARE<span class="Sup">Â®</span> is administered orally, without regard to meals (<a href="#_2__DOSAGE_AND">2</a>). </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>0.6 mg Capsules (<a href="#_3__DOSAGE_FORMS">3</a>).</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given MITIGARE<span class="Sup">Â®</span> in conjunction with drugs that inhibit both P-gp and CYP3A4 (4).  <br>
</li>
<li>Patients with both renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given MITIGARE<span class="Sup">Â®</span> (<a href="#_4__CONTRAINDICATIONS">4</a>).</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span></span> have been reported with colchicine in adults and children. Keep MITIGARE<span class="Sup">Â®</span> out of the reach of children (<a href="#_5_1__Fatal">5.1</a>, <a href="#_10__OVERDOSAGE">10</a>).<br>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span></span>: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported (<a href="#_5_2__Blood">5.2</a>).<br>
</li>
<li>Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine (<a href="#_5_2__Blood">5.2</a>, <a href="#_5_3__Interactions">5.3</a>, <a href="#_5_4__Neuromuscular">5.4</a>, <a href="#_6__ADVERSE_REACTIONS">6</a>, <a href="#_10__OVERDOSAGE">10</a>).<br>
</li>
<li>
<span class="Italics">Drug interaction with dual P-gp and CYP3A4 inhibitors</span>: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<a href="#_5_3__Interactions">5.3</a>, <a href="#_7__DRUG_INTERACTIONS">7</a>).
		Â Â Â Â Â 
	<br>
</li>
<li>
<span class="Italics">Neuromuscular toxicity</span>: Myotoxicity including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> may occur, especially in combination with other drugs known to cause this effect. Consider temporary interruption or discontinuation of MITIGARE<span class="Sup">Â®</span> (<a href="#_5_4__Neuromuscular">5.4</a>, <a href="#_7__DRUG_INTERACTIONS">7</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions with colchicine are <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Hikma Americas, Inc. at 1-877-233-2001 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Co-administration of P-gp or CYP3A4 inhibitors or inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin or cyclosporine) have been reported to lead to colchicine toxicity. The potential for drug-drug interactions must be considered prior to and during therapy.<br>
</li>
<li>Concomitant use of MITIGARE<span class="Sup">Â®</span> and inhibitors of CYP3A4 or P-gp should be avoided if possible. If co-administration of MITIGARE<span class="Sup">Â®</span> and an inhibitor of CYP3A4 or P-gp is necessary, the dose of MITIGARE<span class="Sup">Â®</span> should be reduced and the patient should be monitored carefully for colchicine toxicity (<a href="#_7__DRUG_INTERACTIONS">7</a>, <a href="#_12_3_Pharmacokinetics">12.3</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>In the presence of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, patients should be monitored closely and dose adjustment should be considered as necessary (<a href="#_8_6__Renal">8.6</a>, <a href="#_8_7__Hepatic">8.7</a>).<br>
</li>
<li>Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (<a href="#_8_1__Use">8.1</a>).<br>
</li>
<li>Nursing Mothers: Caution should be exercised when administered to a nursing woman (<a href="#_8_3__Use">8.3</a>). <br>
</li>
<li>Geriatric Use: The recommended dose of colchicine should be based on renal/hepatic function (<a href="#Reference85">8.5</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1. </span><span class="Bold">INDICATION</span><span class="Bold">S</span><span class="Bold"> AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2. </span><span class="Bold">DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1.   <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span> Prophylaxis</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3. </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4. </span><span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5. </span><span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1  Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2  <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3  Interactions with CYP3A4 and P-gp Inhibitors</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4  Neuromuscular Toxicity</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6. </span><span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h1><a href="#section-7" class="toc"><span class="Bold">7. </span><span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1  CYP3A4</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2  P-glycoprotein</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3  HMG-CoA Reductase Inhibitors and Fibrates</span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.4  Drug-Drug Interaction Studies</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8. </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1  Use in Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2 Labor and Delivery</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3  Use in Nursing Mothers</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.</span><span class="Bold">4</span><span class="Bold">  Pediatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.</span><span class="Bold">5</span><span class="Bold">  Geriatric Use</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.</span><span class="Bold">6</span><span class="Bold">  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-8.7" class="toc"><span class="Bold">8.</span><span class="Bold">7</span><span class="Bold">  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">9. </span><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">10. </span><span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">11. </span><span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-12" class="toc"><span class="Bold">12. </span><span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">12.1 Mechanism of Action</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">12.3 Pharmacokinetics</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">13. </span><span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">14. </span><span class="Bold">CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16. </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h2><a href="#section-15.1" class="toc"><span class="Bold">16.1 How Supplied</span></a></h2>
<h2><a href="#section-15.2" class="toc"><span class="Bold">16.2  Storage</span></a></h2>
<h1><a href="#section-16" class="toc"><span class="Bold">17. </span><span class="Bold">PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_1__INDICATIONS_AND"></a><a name="section-1"></a><p></p>
<h1>
<span class="Bold">1. </span><span class="Bold">INDICATION</span><span class="Bold">S</span><span class="Bold"> AND USAGE</span>
</h1>
<p class="First">MITIGARE<span class="Sup">Â®</span> (colchicine) capsules are indicated for prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in adults.</p>
<p>Limitations of use:Â The safety and effectiveness of MITIGARE<span class="Sup">Â®</span> for acute treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> duringÂ prophylaxis has not been studied.</p>
<p>MITIGARE<span class="Sup">Â®</span> is not an analgesic medication and should not be used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from other causes. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_2__DOSAGE_AND"></a><a name="section-2"></a><p></p>
<h1>
<span class="Bold">2. </span><span class="Bold">DOSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1.   <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span> Prophylaxis</span></h2>
<p class="First">For prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, the recommended dosage of MITIGARE<span class="Sup">Â®</span> is 0.6 mg once or twice daily.  The maximum dose is 1.2 mg per day.</p>
<p>MITIGARE<span class="Sup">Â®</span> is administered orally, without regard to meals.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3__DOSAGE_FORMS"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3. </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">0.6 mg capsules <span class="Bold">- </span>No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed â€œWest-ward 118â€? in white ink.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_4__CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4. </span><span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given MITIGARE<span class="Sup">Â®</span> with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <span class="Italics">Drug Interactions</span> (<a href="#_7__DRUG_INTERACTIONS">7</a>)]. Combining these dual inhibitors with colchicine in patients with renal orÂ <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has resulted in life-threatening or fatal colchicine toxicity. </p>
<p>Patients with bothÂ renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given MITIGARE<span class="Sup">Â®</span>.  </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>
<span class="Bold">5. </span><span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_1__Fatal"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1  Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></h2>
<p class="First">Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See <span class="Italics">Overdosage</span> (<a href="#_10__OVERDOSAGE">10</a>)].  MITIGARE<span class="Sup">Â®</span> should be kept out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_2__Blood"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2  <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported with colchicine used in therapeutic doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_3__Interactions"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3  Interactions with CYP3A4 and P-gp Inhibitors</span></h2>
<p class="First">Because colchicine is a substrate for both the CYP3A4 metabolizing enzyme and the P-glycoprotein efflux transporter, inhibition of either of these pathways may lead to colchicine-related toxicity. Inhibition of both CYP3A4 and P-gp by dual inhibitors such as clarithromycin has been reported to produce life-threatening or fatal colchicine toxicity due to significant increases in systemic colchicine levels. Therefore, concomitant use of MITIGARE<span class="Sup">Â®</span> and inhibitors of CYP3A4 or P-glycoprotein should be avoided [<span class="Italics">See</span>Â <span class="Italics">Drug Interactions</span> (<a href="#_7__DRUG_INTERACTIONS">7</a>)].Â Â If avoidance is not possible, reduced daily dose should be considered and the patient should be monitored closely for colchicine toxicity. Use of MITIGARE<span class="Sup">Â®</span> in conjunction with drugs that inhibit both P-gp and CYP3A4 is contraindicated in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [See <span class="Italics">Contraindications</span>Â (<a href="#_4__CONTRAINDICATIONS">4</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_4__Neuromuscular"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4  Neuromuscular Toxicity</span></h2>
<p class="First">Neuromuscular toxicity and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported from chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect.  Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and elderly patients (even those with normal renal and hepatic function) are at increased risk.  Once colchicine treatment is ceased, the symptoms generally resolve within 1 week to several months.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_6__ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">6. </span><span class="Bold">ADVERSE REACTIONS</span>
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span> are the most common adverse reactions with colchicine.  They areÂ often the first signs of toxicity and may indicate that the colchicine dose needs to be reduced or therapy stopped.  These include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p>Colchicine has been reported to cause neuromuscular toxicity, which may present as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> [see <span class="Italics">Warnings and Precautions (</span><span class="Italics"><a href="#_5_4__Neuromuscular">5.4</a></span><span class="Italics">)</span>].</p>
<p>Toxic manifestations associated with colchicine include <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, and injury to cells in the renal, hepatic, circulatory, and central nervous system.  These most often occur with excessive accumulation or overdosage [see <span class="Italics">Overdosage (</span><span class="Italics"><a href="#_10__OVERDOSAGE">10</a></span><span class="Italics">)</span>].</p>
<p>The following reactions have been reported with colchicine.  These have been generally reversible by interrupting treatment or lowering the dose of colchicine:</p>
<p><span class="Bold">Digestive</span>:  abdominal cramping, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4143342" conceptname="Lactose intolerance">lactose intolerance</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold">Neurological</span>: sensory motor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span></p>
<p><span class="Bold">Dermatological</span>: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold">Hematological</span>:  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span></p>
<p><span class="Bold">Hepatobiliary</span>: elevated AST, elevated ALT</p>
<p><span class="Bold">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, elevated CPK, <span class="product-label-link" type="condition" conceptid="4142183" conceptname="Myotonia">myotonia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span></p>
<p><span class="Bold">Reproductive</span>: <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_7__DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>
<span class="Bold">7. </span><span class="Bold">DRUG INTERACTIONS</span>
</h1>
<p class="First">Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme.  Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein.  Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine).</p>
<p>Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given MITIGARE<span class="Sup">Â®</span> with drugs that inhibit both P-glycoprotein and CYP3A4 [See <span class="Italics">Contraindications</span>Â (<a href="#_4__CONTRAINDICATIONS">4</a>)]. Combining these dual inhibitors with MITIGARE<span class="Sup">Â®</span> in patients with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has resulted in life-threatening or fatal colchicine toxicity. </p>
<p>Physicians should ensure that patients are suitable candidates for treatment with MITIGARE<span class="Sup">Â®</span> and remain alert for signs and symptoms of toxic reactions associated with increased colchicine exposure due to drug interactions.  Signs and symptoms of colchicine toxicity should be evaluated promptly and, if toxicity is suspected, MITIGARE<span class="Sup">Â®</span> should be discontinued immediately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_7_1__CYP3A4"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1  CYP3A4</span></h2>
<p class="First">The concomitant use of MITIGARE<span class="Sup">Â®</span> and CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, grapefruit juice, erythromycin, verapamil, etc.) should be avoided due to the potential for serious and life-threatening toxicity [See <span class="Italics">Warnings and Precautions</span> (<a href="#_5_3__Interactions">5.3</a>) and <span class="Italics">Clinical Pharmacology</span> (<a href="#_12__CLINICAL_PHARMACOLOGY">12</a>)].</p>
<p>If co-administration of MITIGARE<span class="Sup">Â®</span> and a CYP3A4 inhibitor is necessary, the dose of MITIGARE<span class="Sup">Â®</span> should be adjusted by either reducing the daily dose or reducing the dose frequency, and the patient should be monitored carefully for colchicine toxicity [See <span class="Italics">Clinical Pharmacology</span> (<a href="#_12__CLINICAL_PHARMACOLOGY">12</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_7_2__P_glycoprotein"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2  P-glycoprotein</span></h2>
<p class="First">The concomitant use of MITIGARE<span class="Sup">Â®</span> and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicityÂ [See <span class="Italics">Warnings and Precautions</span> (<a href="#_5_3__Interactions">5.3</a>) and <span class="Italics">Clinical Pharmacology</span> (<a href="#_12__CLINICAL_PHARMACOLOGY">12</a>)].</p>
<p>If co-administration of MITIGARE<span class="Sup">Â®</span> and a P-gp inhibitor is necessary, the dose of MITIGARE<span class="Sup">Â®</span> should be adjusted by either reducing the daily dose or reducing the dose frequency, and the patient should be monitored carefully for colchicine toxicity [SeeÂ <span class="Italics">Clinical Pharmacology</span> (<a href="#_12__CLINICAL_PHARMACOLOGY">12</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">7.3  HMG-CoA Reductase Inhibitors and Fibrates</span></h2>
<p class="First">Some drugs such as HMG-CoA reductase inhibitors and fibrates may increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> when combined with MITIGARE<span class="Sup">Â®</span>.  Complaints of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> could be an indication to check serum creatinine kinase levels for signs of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">7.4  Drug-Drug Interaction Studies</span></h2>
<p class="First">Four pharmacokinetic studies evaluated the effects of co-administration of voriconazole (200 mg BID), fluconazole (200 mg QD), cimetidine (800 mg BID), and propafenone (225 mg BID) on systemic levels of colchicine. Colchicine can be administered with these drugs at the tested doses without a need for dose adjustment. However, these results should not be extrapolated to other co-administered drugs [See <span class="Italics">Drug-Drug Interactions (</span><span class="Italics"><a href="#_7_1__CYP3A4">7.1</a></span><span class="Italics">, </span><span class="Italics"><a href="#_7_2__P_glycoprotein">7.2</a></span><span class="Italics">) and </span><span class="Italics">Pharmacokinetics</span> (<a href="#_12_3_Pharmacokinetics">12.3</a>)]. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8. </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="_8_1__Use"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1  Use in Pregnancy</span></h2>
<p class="First"><span class="Underline">Pregnancy Category C</span>.  There are no adequate and well-controlled studies with MITIGARE<span class="Sup">Â®</span> in pregnant women. Colchicine crosses the human placenta. Developmental studies in animals were not conducted with MITIGARE<span class="Sup">Â®</span>, however published animal reproduction and development studies with colchicine demonstrated embryofetal toxicity, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, and altered postnatal development at exposures within or above the clinical therapeutic range. Colchicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.2 Labor and Delivery</span></h2>
<p class="First">The effect of colchicine on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="_8_3__Use"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.3  Use in Nursing Mothers</span></h2>
<p class="First">Colchicine is excreted into human milk. Limited information suggests that infants exclusively breastfed receive less than 10 percent of the maternal weight-adjusted dose. While there are no published reports of adverse effects in breast-feeding infants of mothers taking colchicine, colchicine can affect gastrointestinal cell renewal and permeability. Caution should be exercised and breastfeeding infants should be observed for adverse effects when MITIGARE<span class="Sup">Â®</span>Â is administered to a nursing woman.   </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">4</span><span class="Bold">  Pediatric Use</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span> is rare in pediatric patients; the safety and effectiveness of MITIGARE<span class="Sup">Â®</span> in pediatric patients has not been evaluated in controlled studies. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Reference85"></a><a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">5</span><span class="Bold">  Geriatric Use</span>
</h2>
<p class="First">Because of the increased incidence of decreased renal function in the elderly population, and the higher incidence of other co-morbid conditions in the elderly population requiring the use of other medications, reducing the dosage of colchicine when elderly patients are treated with colchicine should be carefully considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_6__Renal"></a><a name="section-8.6"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">6</span><span class="Bold">  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>
</h2>
<p class="First">No dedicated pharmacokinetic study has been conducted using MITIGARE<span class="Sup">Â®</span> in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Colchicine is known to be excreted in urine in humans and the presence of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been associated with colchicine toxicity. Urinary clearance of colchicine and its metabolites may be decreased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Dose reduction or alternatives should be considered for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Colchicine is not effectively removed by hemodialysis. Patients who are undergoing hemodialysis should be monitored carefully for colchicine toxicity. Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_7__Hepatic"></a><a name="section-8.7"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">7</span><span class="Bold">  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>
</h2>
<p class="First">No dedicated pharmacokinetic study using MITIGARE<span class="Sup">Â®</span> has been conducted in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Colchicine is known to be metabolized in humans and the presence of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has been associated with colchicine toxicity. Hepatic clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>Dose reduction or alternatives should be considered for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">9. </span><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span>
</h1>
<p class="First">Tolerance, abuse, or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> from colchicine has not been reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="_10__OVERDOSAGE"></a><a name="section-10"></a><p></p>
<h1>
<span class="Bold">10. </span><span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First">The dose of colchicine that would induce significant toxicity for an individual is unknown. Fatalities have been reported in patients after ingesting a dose as low as 7 mg over a 4-day period, while other patients have reportedly survived after ingesting more than 60 mg. A review of 150 patients who overdosed on colchicine found that those who ingested less than 0.5 mg/kg survived and tended to have milder adverse reactions, such as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, whereas those who ingested from 0.5 to 0.8 mg/kg had more severe adverse reactions, including <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. There was 100% mortality among patients who ingested more than 0.8Â mg/kg.</p>
<ul class="Disc">
<li>The first stage of acute colchicine toxicity typically begins within 24 hours of ingestion and includes <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and significant <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span>, leading to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>. Peripheral <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> may also be seen. <br>
</li>
<li>Life-threatening complications occur during the second stage, which occurs 24 to 72 hours after drug administration, attributed to multi-organ failure and its associated consequences. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> usually results from <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. If the patient survives, recovery of multi-organ injury may be accompanied by rebound <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> starting about 1 week after the initial ingestion. <br>
</li>
<li>Treatment of colchicine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should begin with gastric lavage and measures to prevent <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. Colchicine is not effectively removed by hemodialysis [See<span class="Italics">Â </span><span class="Italics">Pharmacokinetics</span> (<a href="#_12_3_Pharmacokinetics">12.3</a>)].</li>
</ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">11. </span><span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">Colchicine is an alkaloid obtained from the plant <span class="Italics">colchicum autumnale</span>. </p>
<p>The chemical name for colchicine is (<span class="Italics">S)-N-</span>(5,6,7,9- tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol[a]heptalen-7-yl) acetamide. The structural formula is represented below:</p>
<p><img alt="Structural Formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2&amp;name=mitigare-01.jpg"></p>
<p>Colchicine consists of <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow scales or powder; it darkens on exposure to light. Colchicine is soluble in water, freely soluble in alcohol, and slightly soluble in ether. </p>
<p>MITIGARE<span class="Sup">Â®</span> (colchicine) capsules are supplied for oral administration. Each capsule contains 0.6 mg Colchicine and the following inactive ingredients:  colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The capsule shell contains gelatin, purified water, titanium dioxide, erythrosine, Brilliant Blue FCF and Quinoline Yellow.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="_12__CLINICAL_PHARMACOLOGY"></a><a name="section-12"></a><p></p>
<h1>
<span class="Bold">12. </span><span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action</span></h2>
<p class="First">Colchicineâ€™s effectiveness as a treatment for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> has been postulated to be due to its ability to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. ColchicineÂ disrupts the polymerization of Î²-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> to sites of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.  Colchicine also interferes with the inflammasome complex found in <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and monocytes that mediates interleukin-1Î² (IL-1Î²) activation.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="_12_3_Pharmacokinetics"></a><a name="section-12.2"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics</span></h2>
<p class="First"><span class="Underline">Absorption</span></p>
<p>In healthy adults, MITIGARE<span class="Sup">Â®</span> when given orally reached a mean C<span class="Sub">max</span> of 3 ng/mL in 1.3 h (range 0.7 to 2.5 h) after 0.6 mg single dose administration.</p>
<p>Absolute bioavailability is reported to be approximately 45%.</p>
<p>Administration with food has no effect on the rate or extent of colchicine absorption.</p>
<p>Colchicine is not effectively removed by hemodialysis.</p>
<p><span class="Underline">Distribution</span></p>
<p>Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8Â L/kg. Colchicine binding to serum protein is about 39%,  primarily to albumin.  Colchicine crosses the placenta and distributes into breast milk [See <span class="Italics">Pregnancy</span><span class="Italics">Â </span>(<a href="#_8_1__Use">8.1</a>) and <span class="Italics">Nursing Mothers</span> (<a href="#_8_3__Use">8.3</a>)].</p>
<p><span class="Underline">Metabolism</span></p>
<p>A published in vitro human liver microsome study showed that about 16% of colchicine is metabolized to 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively) by CYP3A4. Glucuronidation is also believed to be a metabolic pathway for colchicine. </p>
<p><span class="Underline">Excretion</span></p>
<p>In a published study in healthy volunteers, 40 to 65% of the total absorbed dose of colchicine (1 mg administered orally) was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also believed to play a role in colchicine elimination. Colchicine is a substrate of P-gp and P-gp efflux is postulated to play an important role in colchicine disposition. Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).</p>
<p><span class="Underline">Special Populations</span>Â </p>
<p>There is no difference between men and women in the pharmacokinetic disposition of colchicine.</p>
<p><span class="Bold Italics">Pediatric Patients:</span> Pharmacokinetics of colchicine was not evaluated in pediatric patients.</p>
<p><span class="Bold Italics">Elderly:</span> Pharmacokinetics of colchicine have not been determined in elderly patients. A published report described the pharmacokinetics of 1 mg oral colchicine tablet in four elderly women compared to six young healthy males. The mean age of the four elderly women was 83 years (range 75 to 93), mean weight was 47 kg (38 to 61 kg) and mean creatinine clearance was 46 mL/min (range 25 to 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males. It is possible that the higher exposure in the elderly subjects was due to decreased renal function. </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> Pharmacokinetics of colchicine in patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not known. A published report described the disposition of colchicine (1 mg) in young adult men and women patients who had end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring dialysis compared to patients with normal renal function. Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hrs vs. 4.4 hrs) as compared to subjects with normal renal function [See<span class="Italics">Â </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><span class="Italics"> (</span><span class="Italics"><a href="#_8_6__Renal">8.6</a></span><span class="Italics">)</span>].</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> Published reports on the pharmacokinetics of intravenous colchicine in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>, as well as those with alcoholic or <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span>, and normal renal function suggest wide inter-patient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span>, no consistent trends were noted [See <span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><span class="Italics"> (</span><span class="Italics"><a href="#_8_7__Hepatic">8.7</a></span><span class="Italics">)</span>]. No pharmacokinetic data are available for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C).</p>
<p><span class="Underline">Drug</span><span class="Underline"> Interactions</span></p>
<p>Pharmacokinetic studies evaluating changes in systemic levels of colchicine when co-administered with CYP3A4 inhibitors in healthy volunteers have been conducted with MITIGARE<span class="Sup">Â®</span>. While voriconazole 200Â mg BID for 5 days (considered a strong CYP3A4 inhibitor) and cimetidine 800 mg BID for 5 days (considered a weak CYP3A4 inhibitor) did not cause any changes in colchicine systemic levels, fluconazole 200 mg QD for 4 days with a 400 mg loading dose (considered a moderate CYP3A4 inhibitor) increased colchicine AUC by 40%. As voriconazole, cimetidine, and fluconazole are known as CYP3A4 inhibitors that do not inhibit P-gp, these studies show that CYP3A4 inhibition by itself may not lead to clinically significant increases in colchicine systemic levels in humans, and P-gp inhibition in addition to CYP3A4 inhibition may be necessary for clinically meaningful interactions of colchicine. However, based on published case reports that indicate the presence of colchicine toxicity when colchicine is co-administered with strong to moderate CYP3A4 inhibitors such as clarithromycin, erythromycin, grapefruit juice, etc., as well as the 40% increase in systemic levels of colchicine observed with concomitantly administered fluconazole (a moderate CYP3A4 inhibitor that is not known to inhibit P-gp) in a drug-drug interaction study, the drug-drug interaction potential of colchicine with strong or moderate CYP3A4 inhibitors that do not inhibit P-gp cannot be ruled out completely. </p>
<p>Co-administration of MITIGARE<span class="Sup">Â®</span> with propafenone (a P-gp inhibitor) at 225 mg BID for 5 days, in a pharmacokinetic study in healthy volunteers, did not cause any changes in systemic levels of colchicine. This indicates that propafenone can be administered with MITIGARE<span class="Sup">Â®</span> without any dose adjustment. However, these results should not be extrapolated to other P-gp inhibitors as colchicine is known to be a substrate for P-gp and case reports of colchicine toxicity associated with the co-administration of P-gp inhibitors such as cyclosporine have been published.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">13. </span><span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First"><span class="Bold Italics">Carcinogenesis</span><br>Carcinogenicity studies of colchicine have not been conducted. Due to the potential for colchicine to produce aneuploid cells (cells with an unequal number of chromosomes), colchicine presents a theoretical increased risk of malignancy.</p>
<p><span class="Bold Italics">Mutagenesis</span><br>Published studies demonstrated that colchicine was negative for mutagenicity in the bacterial reverse mutation assay. However, in vitro chromosomal aberration assaysÂ demonstrated the formation of micronuclei following colchicine treatment. Because published studies demonstrated that colchicine induces aneuploidyÂ through the process of mitotic nondisjunction without structural DNA changes, colchicine is not considered clastogenic, although micronuclei are formed.</p>
<p><span class="Bold Italics">Impairment of Fertility</span><br>There were no studies of the effects of MITIGARE<span class="Sup">Â®</span> on fertility. However, published nonclinical studies have demonstrated that colchicine-induced disruption of microtubule formation affects meiosis and mitosis. Published reproductive studies with colchicine reported abnormal sperm morphology and reduced sperm counts in males, and interference with sperm penetration, second meiotic division, and normal cleavage in females.</p>
<p>Case reports and epidemiology studies in human male subjects on colchicine therapy indicate that <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> from colchicine is rare. A case report indicated that <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> was reversed when therapy was stopped. Case reports and epidemiology studies in female subjects on colchicine therapy have not established a clear relationship between colchicine use and <span class="product-label-link" type="condition" conceptid="197606" conceptname="Female infertility of tubal origin">female infertility</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">14. </span><span class="Bold">CLINICAL STUDIES</span>
</h1>
<p class="First">The evidence for the efficacy of colchicine in patients with chronic <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> is derived from the published literature. Two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> initiating treatment with urate lowering therapy. In both trials, treatment with colchicine decreased the frequency of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">16. </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15.1"></a><p></p>
<h2><span class="Bold">16.1 How Supplied</span></h2>
<p class="First">MITIGARE<span class="Sup">Â®</span> (colchicine) capsules, 0.6 mg are No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed â€œWest-ward 118â€? in white ink.</p>
<p>Bottles of 100 capsules</p>
<p>Bottles of 1000 capsules</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.2"></a><p></p>
<h2><span class="Bold">16.2  Storage</span></h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>Protect from light and moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>
<span class="Bold">17. </span><span class="Bold">PATIENT COUNSELING INFORMATION</span>
</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (<a href="#MedicationGuide">Medication Guide</a>).  </p>
<p><span class="Bold">Dosing Instructions</span></p>
<p>If a dose of MITIGARE<span class="Sup">Â®</span> is missed, advise the patient to take the dose as soon as possible and then return to the normal dosing schedule. However, if a dose is skipped, the patient should not double the next dose. </p>
<p><span class="Bold">Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></p>
<p>Advise the patient that fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, both accidental and intentional, have been reported in adults and children who have ingested colchicine. MITIGARE<span class="Sup">Â®</span> should be kept out of the reach of children.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></span></p>
<p>Advise patients that <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> with <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may occur with MITIGARE<span class="Sup">Â®</span>.</p>
<p><span class="Bold">Drug and Food Interactions</span></p>
<p>Advise patients that many drugs or other substances may interact with MITIGARE<span class="Sup">Â®</span> and some interactions could be fatal. Therefore, patients should report to their healthcare provider all of the current medications they are taking, and check with their healthcare provider before starting any new medications, including short-term medications such as antibiotics. Patients should also be advised to report the use of non-prescription medication or herbal products. Grapefruit and grapefruit juice may also interact and should not be consumed during treatment with MITIGARE<span class="Sup">Â®</span>.</p>
<p><span class="Bold">Neuromuscular Toxicity</span></p>
<p>Advise patients that <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in fingers or toes may occur with MITIGARE<span class="Sup">Â®</span> alone or when it is used with certain other drugs. Patients developing any of these signs or symptoms must discontinue MITIGARE<span class="Sup">Â®</span> and seek medical evaluation immediately.</p>
<p>Manufactured for:<br><span class="Bold">Hikma Americas, Inc.</span><br>Memphis, TN  38120</p>
<p>Manufactured by:<br><span class="Bold">West-Ward Pharmaceutical</span><span class="Bold">s</span><span class="Bold"> Corp.</span><br>Eatontown, NJ 07724</p>
<p>Revised: July 2015<br>Rx Only</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MedicationGuide"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">Â </span>(mÄ«t-ah-gÃ¤r-ay) <span class="Bold">Capsules</span></p>
<p><span class="Bold">What is the most important information I should know about </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<p>MITIGARE<span class="Sup">Â®</span>Â can cause serious side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if levels of MITIGARE<span class="Bold"><span class="Sup">Â®</span></span> are too high in your body.</p>
<ul class="Disc">
<li>Taking certain medicines with MITIGARE<span class="Sup">Â®</span> can cause your level of MITIGARE<span class="Sup">Â®</span> to be too high, especially if you have kidney or liver problems.  <br>
</li>
<li>Tell your healthcare provider about all your medical conditions, including if you have kidney or liver problems. Your dose of MITIGARE<span class="Sup">Â®</span> may need to be changed.<br>
</li>
<li>Even medicines that you take for a short period of time, such as antibiotics, can interact with MITIGARE<span class="Sup">Â®</span> and cause serious side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </li>
</ul>
<p><span class="Bold">What is </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<p>MITIGARE<span class="Sup">Â®</span> is a prescription medication used to prevent <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in adults.  </p>
<p>It is not known if MITIGARE<span class="Sup">Â®</span> is safe and effective for the treatment of: </p>
<ul class="Disc"><li>acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> </li></ul>
<p>MITIGARE<span class="Sup">Â®</span> is not a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine and it should not be taken to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> related to other conditions unless specificallyÂ for those conditions.</p>
<p>It is not known if MITIGARE<span class="Sup">Â®</span> is safe and effective in children.</p>
<p><span class="Bold">Who should not take </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<p><span class="Bold">Do not</span> take MITIGARE<span class="Sup">Â®</span> if you have liver and kidney problems and you take certain other medicines. Serious side effects, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in these people even when taken as directed. See <span class="Bold">â€œWhat is the most important information I should know about </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?â€?</span></p>
<p><span class="Bold">What should I tell my healthcare provider before taking </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<p>Before you take MITIGARE<span class="Sup">Â®</span>, tell your healthcare provider:</p>
<ul class="Disc">
<li>about all of your medical conditions <br>
</li>
<li>if you have kidney or liver problems <br>
</li>
<li>if you are pregnant or plan to become pregnant. It is not known if MITIGARE<span class="Sup">Â®</span> can harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.<br>
</li>
<li>if you are breastfeeding or plan to breastfeed. MITIGARE<span class="Sup">Â®</span> can pass into your breast milk and may harm your baby.  Talk to your healthcare provider about the best way to feed your baby if you take MITIGARE<span class="Sup">Â®</span>.</li>
</ul>
<p><span class="Bold">Tell </span><span class="Bold">your healthcare provider about all the medicines you take,</span> including prescription, over-the-counter medicines, vitamins, or herbal supplements. </p>
<ul class="Disc">
<li>Using MITIGARE<span class="Sup">Â®</span> with certain other medicines can affect each other causing serious side effects and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <br>
</li>
<li>Do not take MITIGARE<span class="Sup">Â®</span> with other medicines unless your healthcare provider tells you to. <br>
</li>
<li>Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist each time you get a new medicine.</li>
</ul>
<ul class="Disc"><li>Especially tell your healthcare provider if you take:Â <ul class="Circle">
<li>medicines that may affect how your liver works (CYP3A4 inhibitors)<br>
</li>
<li>cyclosporine (NeoralÂ®, GengrafÂ®, SandimmuneÂ®)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering medicines<br>
</li>
<li>antibiotics</li>
</ul>
</li></ul>
<p>Ask your healthcare provider or pharmacist if you are not sure if you take any of the medicines listed above. This is not a complete list of all the medicines that can affect MITIGARE<span class="Sup">Â®</span>. </p>
<p><span class="Bold">How should I take </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<ul class="Disc">
<li>Take MITIGARE<span class="Sup">Â®</span> exactly as your healthcare provider tells you to take it. <br>
</li>
<li>MITIGARE<span class="Sup">Â®</span> can be taken with or without food.<br>
</li>
<li>If you take too much MITIGARE<span class="Sup">Â®</span> call your healthcare provider or go to the nearest hospital emergency room right away.<br>
</li>
<li>Do not stop taking MITIGARE<span class="Sup">Â®</span> unless your healthcare provider tells you to.<br>
</li>
<li>If you miss a dose of MITIGARE<span class="Sup">Â®</span>, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses at the same time.<br>
</li>
<li>If you have a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> while taking MITIGARE<span class="Sup">Â®</span>, tell your healthcare provider.</li>
</ul>
<p><span class="Bold">What should I avoid while taking </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<ul class="Disc"><li>Avoid eating grapefruit or drinking grapefruit juice while taking MITIGARE<span class="Sup">Â®</span>. It can increase your chances of getting serious side effects.<ul class="Circle">
<li>unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span><br>
</li>
<li>increased <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your fingers or toes<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> or gray color to your lips, tongue, or palms of your hands<br>
</li>
<li>severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
</li></ul>
<p><span class="Bold">What are the possible side effects of </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<p>MITIGARE<span class="Sup">Â®</span> can cause serious side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<span class="Bold">Â </span>See<span class="Bold"> â€œWhat is the most important information I </span><span class="Bold">should know about MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?â€?</span></p>
<p>Get medical help right away, if you have:</p>
<p>The most common side effects of MITIGARE<span class="Sup">Â®</span>Â include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of MITIGARE<span class="Sup">Â®</span>. For more information ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<ul class="Disc">
<li>Store MITIGARE<span class="Sup">Â®</span> at room temperature between 68Â° to 77Â°F (20Â° to 25Â°C).<br>
</li>
<li>Keep MITIGARE<span class="Sup">Â®</span> in a tightly closed container.<br>
</li>
<li>Keep MITIGARE<span class="Sup">Â®</span> out of the light and away from moisture.</li>
</ul>
<p><span class="Bold">Keep </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold"> and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General </span><span class="Bold">i</span><span class="Bold">nformation about</span><span class="Bold"> the safe and effective use of</span><span class="Bold">Â </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do notÂ takeÂ MITIGARE<span class="Sup">Â®</span> for a condition for which it was not prescribed.  Do not give MITIGARE<span class="Sup">Â®</span> to other people, even if they haveÂ the same symptoms that you have.  It may harm them.   </p>
<p>This Medication Guide summarizesÂ the most important information about MITIGARE<span class="Sup">Â®</span>.Â  If you would like more information, talk to your pharmacist or healthcare provider for information about MITIGARE<span class="Sup">Â®</span> that is written for health professionals.</p>
<p>For more information, go to www.hikma-americas.com or call 1-877-233-2001.</p>
<p><span class="Bold">What are the ingredients in </span><span class="Bold">MITIGARE</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold"> Capsules?</span></p>
<p><span class="Bold">Active Ingredient:</span> Colchicine</p>
<p><span class="Bold">Inactive Ingredients: </span>colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. The capsule shell contains gelatin, purified water, titanium dioxide, erythrosine, Brilliant Blue FCF and Quinoline Yellow.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:<br><span class="Bold">Hikma Americas, Inc.</span><br>Memphis, TN  38120</p>
<p>Manufactured by:<br><span class="Bold">West-Ward Pharmaceutical</span><span class="Bold">s</span><span class="Bold"> Corp.</span><br>Eatontown, NJ 07724</p>
<p>July 2015</p>
<p>Rx Only</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span><br>NDC 59467-318-01<br>MITIGARE<br>(colchicine) Capsules<br>0.6 mg<br>Rx Only<br>100 Capsules</p>
<p><img alt="NDC 59467-318-01
MITIGARE
(colchicine) Capsules
0.6 mg
Rx Only
100 Capsules
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2&amp;name=mitigare-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MITIGAREÂ 		
					</strong><br><span class="contentTableReg">colchicine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59467-318</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>COLCHICINE</strong> (COLCHICINE) </td>
<td class="formItem">COLCHICINE</td>
<td class="formItem">0.6Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Dark/Light Blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">West;ward;118</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59467-318-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59467-318-10</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204820</td>
<td class="formItem">10/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Hikma Americas, Inc.
							(078883518)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>83ac9ccb-f185-43e2-bf6b-31bc7db23c28</div>
<div>Set id: cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2</div>
<div>Version: 8</div>
<div>Effective Time: 20150701</div>
</div>
</div>Â <div class="DistributorName">Hikma Americas, Inc.</div></p>
</body></html>
